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Discovery of an exosite on the SOCS2-SH2 domain
that enhances SH2 binding to phosphorylated
ligands
1234567890():,;

Edmond M. Linossi1,2,6, Kunlun Li1,2,6, Gianluca Veggiani3,6, Cyrus Tan1,2, Farhad Dehkhoda1,2, Colin Hockings1,2,
Dale J. Calleja 1,2, Narelle Keating1,2, Rebecca Feltham 1,2, Andrew J. Brooks 4, Shawn S. Li 5,
Sachdev S. Sidhu 3, Jeffrey J. Babon 1,2, Nadia J. Kershaw 1,2,7 ✉ & Sandra E. Nicholson 1,2,7 ✉

Suppressor of cytokine signaling (SOCS)2 protein is a key negative regulator of the growth
hormone (GH) and Janus kinase (JAK)-Signal Transducers and Activators of Transcription
(STAT) signaling cascade. The central SOCS2-Src homology 2 (SH2) domain is characteristic
of the SOCS family proteins and is an important module that facilitates recognition of targets
bearing phosphorylated tyrosine (pTyr) residues. Here we identify an exosite on the SOCS2SH2 domain which, when bound to a non-phosphorylated peptide (F3), enhances SH2 afﬁnity
for canonical phosphorylated ligands. Solution of the SOCS2/F3 crystal structure reveals F3
as an α-helix which binds on the opposite side of the SH2 domain to the phosphopeptide
binding site. F3:exosite binding appears to stabilise the SOCS2-SH2 domain, resulting in
slower dissociation of phosphorylated ligands and consequently, enhances binding afﬁnity.
This biophysical enhancement of SH2:pTyr binding afﬁnity translates to increase SOCS2
inhibition of GH signaling.
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yrosine phosphorylation is a fundamental step in many
signal transduction cascades required to mediate cellular
processes. The Src homology 2 (SH2) domain forms the
largest family of phosphotyrosine recognition domains, with a
total of 120 different SH2 domains found in 110 distinct proteins
in the human genome1. The binding speciﬁcities between different SH2 domains and the sequence surrounding the phosphotyrosine motif in individual proteins guarantee the accurate
recognition of the target protein and tightly regulated signal
transmission. The SH2 domain is a small protein module consisting of three β-strands ﬂanked by two α-helixes. These secondary structural elements and the loops that connect them form
two pockets; one is the highly conserved phosphotyrosine binding
pocket, and the second is a hydrophobic pocket that typically
accommodates hydrophobic residues in the target protein located
in the “+3” position following the phosphotyrosine2,3.
Members of the Suppressors of Cytokine Signaling (SOCS)
protein family are the primary negative regulators of Janus kinase
(JAK)-signal transducer and activator of transcription protein
(STAT) signaling. Eight members have been identiﬁed, including
CIS and SOCS1-7, which are deﬁned by a central SH2 domain
and a C-terminal SOCS box motif4,5. The SOCS-SH2 domain
conforms to the canonical SH2 domain structural fold and is
distinguished by an additional α-helix N-terminal to the domain,
designated the extended SH2 subdomain (ESS)6–8. Although
some phosphotyrosine motif binding preferences have been
deﬁned for individual SOCS-SH2 domains9–12, the full suite of
protein targets and preferred binding sequences for each SOCSSH2 domain remain to be elucidated. The SOCS proteins themselves have clearly deﬁned biological roles in regulating signaling
cascades activated by different cytokines and growth factors13–19.
The SOCS-SH2 domain is central to their function and in all
instances tested, loss of SH2 binding to phosphotyrosine causes
loss of SOCS activity20–22. The SOCS box, a conserved 40-residue
motif at the C-terminus of the SH2 domain, forms two alphahelices and is constitutively associated with the adaptor proteins
Elongin B and Elongin C, which function to both stabilize the
SH2 domain and recruit an E3 ubiquitin ligase complex consisting of Cullin5 and RING-box protein (Rbx)25,23. This
recruitment allows the ubiquitination and proteasomal degradation of targets bound to the SOCS-SH2 domains and classes the
SOCS proteins as Cullin-RING E3 ligases (CRLs)23.
SOCS2 is the predominant negative regulator of growth hormone (GH) and prolactin signaling13,19,24–26. Consequently,
SOCS2-deﬁcient mice (Socs2−/−) display gigantism, weighing
signiﬁcantly more than their wild-type counterparts at 6 weeks of
age, due to enhanced GH signaling19. SOCS2 regulation of GH
signaling is thought to primarily occur via SOCS2-SH2 domain
recognition of phosphotyrosine Tyr595 in the GH receptor
(GHR)13. However, the paradoxical observation that mice
expressing a Socs2 transgene also display gigantism, remains
mechanistically unexplained24. Several reports indicate an
important role for SOCS2 in immune cells, with Socs2−/− mice
displaying hyper-responsiveness to microbial stimuli in dendritic
cells (DCs) and skewed T helper type 2 (Th2) differentiation and
impaired generation of inducible regulatory T cells (iTregs)27–29.
In addition, Socs2 is upregulated by interferon-gamma (IFNγ) in
DCs in human melanoma, and Socs2−/− mice exhibit enhanced
DC priming of Tcell responses to give improved antitumor
immunity30.
SOCS2 has been reported to inhibit both STAT activation31
and NF-κB signaling; regulating the nuclear translocation of the
NF-κB p65 subunit in DCs32, with primary Socs2−/− hepatocytes
showing increased phospho-p65 in the nucleus compared with
wild-type cells33. SOCS2 clearly has many diverse roles in biological processes that are important for cancer, autoimmunity,
2

and other inﬂammatory diseases. Understanding the function and
recognition speciﬁcity of the SOCS2-SH2 domain is critical to
understanding how SOCS2 regulates these different signaling
cascades.
Here, we have discovered an exosite on the SOCS2-SH2
domain that, when occupied by a peptide (F3), reciprocally
enhances the afﬁnity of the SH2 domain for its canonical phosphorylated ligands. X-ray crystallography and NMR analysis
revealed F3-bound as an α-helix on the opposite side to the
phosphotyrosine binding pocket. F3 binding appeared to stabilize
the ESS helix and phosphotyrosine binding loop, resulting in a
reduced dissociation rate and increased SH2 afﬁnity for its
phosphorylated protein targets. Apart from the closely related
CIS-SH2 domain, F3 binding was highly selective for SOCS2,
with CIS displaying similar, although reduced, enhancement of
afﬁnity for phosphorylated ligands. This suggests the F3:exosite
phenomenon might be applicable to other SH2 domains, with the
cooperative increase in binding afﬁnity implying an unappreciated degree of regulation. Expression of F3 peptide in A549 cells
enhanced SOCS2-SH2 binding to the GHR and increased SOCS2
inhibition of GH signaling. Consequently, biophysical measurement of SH2-binding afﬁnities might be substantially underestimated, particularly if both exosite and canonical sites are
simultaneously occupied by proteins in the same complex.
Results
Identiﬁcation of non-phosphorylated peptides which bind to
the SOCS2-SH2 domain. In order to identify peptides that could
bind to the surface of the SOCS2-SH2 domain, we used a highly
degenerate phage-displayed library encoding random hexadecapeptides containing combinations of all 19 genetically
encoded amino acids except cysteine34. The peptide library was
cycled through ﬁve rounds of selection for binding to a fusion
protein consisting of the SOCS2-SH2 domain and SOCS box
fused to the C-terminus of glutathione S-transferase (GST), in
complex with elongins B and C (GST-SOCS232–198-EloB/C;
SOCS2 lacking the N-terminal region) (Fig. 1a). To maximize the
chances of isolating highly speciﬁc peptides, prior to binding to
the GST-SOCS232–198-EloB/C complex, the library was incubated
with bovine serum albumin (BSA) and GST to deplete the phage
pool of non-speciﬁc peptides. Following biopanning, we used
phage-ELISAs to detect clones that showed binding to the GSTSOCS232–198-EloB/C complex, but not to BSA or GST, and
subjected speciﬁc clones to DNA sequence analysis. Selections
yielded three unique non-phosphorylated peptides that bound
with high afﬁnity to the GST-SOCS232–198-EloB/C complex and
contained a homologous central sequence motif (HLMxKW).
Synthetic peptides bound to SOCS232–198-EloB/C with KD
1.68–19.33 µM, as measured by isothermal calorimetry (ITC)
(Fig. 1b; Supplementary Table 1).
A series of alanine point mutations of the highest afﬁnity
peptide (F3; 1.68 μM) conﬁrmed that the central sequence motif
was absolutely required for binding, whereas mutation to residues
with similar physio-chemical properties, indicated some tolerance
of related residues (with the exception of K10H) (Fig. 1b and
Table 1). The residues N- and C-terminal to the HLMxKW motif
also appeared to contribute to binding, given that the three
homologous peptides displayed varying afﬁnities, and that
truncation of more than two residues from each terminus of
the F3 peptide was sufﬁcient to abrogate binding (Table 1).
F3 did not interact with the SOCS2-SOCS box complex alone
(SOCS2157-198-EloB/C; Supplementary Table 1), nor did the
presence of Cullin5 in the complex impact on F3 binding
(Supplementary Fig. 1), indicating that F3 interacted directly with
the SOCS2-SH2 domain.

NATURE COMMUNICATIONS | (2021)12:7032 | https://doi.org/10.1038/s41467-021-26983-5 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26983-5

The F3 peptide allosterically enhances SOCS2-SH2 domain
binding to phosphorylated proteins. We initially hypothesized
that the F3 peptide would bind the canonical phosphopeptide
binding interface; however, the F3 peptide did not compete with a

Fig. 1 Identiﬁcation of a peptide that binds with low micromolar afﬁnity
to the SOCS2/Elongin B/C complex. a Phage display of a degenerate
peptide library was used to enrich for non-phosphorylated peptides that
bound to SOCS2. GST-SOCS2-SH2-SOCS box protein was produced as a
trimeric complex in E. coli by co-expression with elongins B and C. Protein
was produced with an N-terminal GST tag and lacks the SOCS2-N-terminal
region [GST-SOCS232–198-EloB/C]. b Three peptide sequences that shared
amino-acid sequence homology were enriched by phage display. Colors
indicate amino-acid similarity. *indicates mutation to Ala = loss of binding.
ITC was used to determine the binding afﬁnities (KD) of the individual
peptides (shown on the right) (related to Table 1).

tyrosine-phosphorylated peptide (pY595) derived from the GHR.
Instead, the presence of F3 unexpectedly enhanced SOCS2
binding to the GHR pY595 peptide (~20-fold increase from
0.70 μM to 0.04 μM) (Fig. 2a). The effect was reciprocal, with the
GHR peptide, in turn, enhancing SOCS2 binding to F3, in
addition to the homologous E4 and F11 peptides (Fig. 2b, d and
Supplementary Table 1). The impact of F3 on SOCS2-SH2 afﬁnity for GHR pY595 was further validated by competition SPR
(~10-fold increase; Supplementary Fig. 2a). The difference
between ITC and SPR (0.04 c.f. 0.15 μM in the presence of F3)
was within acceptable experimental variation, and subsequent
experiments were performed using SPR owing to its higher
throughput and sensitivity. The F3-driven enhancement was not
restricted to the GHR pY595 peptide, as SOCS2 also displayed an
enhanced afﬁnity for tyrosine-phosphorylated peptides derived
from murine gp130 pY757 and erythropoietin (EPO) receptor
Y426 (Supplementary Table 1). We also examined the F3:SOCS2
interaction using a thermal stability assay. F3 binding showed a
clear stabilization effect on both the apo and phosphopeptidebound forms, as expected. F3 binding increased the melting
temperature (TM) of SOCS2 by 5.8 degrees, whereas binding of a
phosphorylated ligand increased the TM by 13.0 degrees. The
combination of F3 and phosphopeptide resulted in a further
increase in TM, which was not completely additive (Supplementary Fig. 2b). Given that the SOCS2 construct used in SPR
and ITC experiments lacked the N-terminal region, we veriﬁed
that F3 bound to full-length SOCS21–198-EloB/C with a similar
afﬁnity and enhancement of phosphopeptide binding, as that
observed for the truncated SOCS232–198-EloB/C construct (Supplementary Fig. 2a). This suggests that the N-terminal region
does not occupy the allosteric site on the SOCS2-SH2 domain.
To conﬁrm that F3 enhanced binding of the SOCS2-SH2
domain to intact phosphorylated proteins, HepG2 cells were
treated with pervanadate to increase global phosphorylation,
lysed and GST or GST-SOCS232–198-EloB/C used to enrich
phosphorylated proteins. GST-SOCS232–198-EloB/C speciﬁcally
enriched tyrosine-phosphorylated proteins (identiﬁed by GHR
pY595 competition) and this was enhanced in the presence of the
F3 peptide, including detection of additional interacting phosphoproteins (Fig. 2c). We next investigated F3:SOCS2 interaction in
live HEK293T cells, using ﬂuorescence lifetime imaging microscopy (FLIM). Representative images showed lower ﬂuorescence
lifetimes in cells expressing SOCS2 and mRuby3-F3, compared
with cells expressing only SOCS2, or SOCS2 and mRuby3

Table 1 Mutation of F3 peptide impacts on binding to SOCS2.
Peptides
F3
H6A
L7A
M8A
D9A
K10A
W11A

Sequences
D
I
D
I
D
I
D
I
D
I
D
I
D
I

A
A
A
A
A
A
A

L
L
L
L
L
L
L

Q
Q
Q
Q
Q
Q
Q

H
A
H
H
H
H
H

L
L
A
L
L
L
L

M
M
M
A
M
M
M

D
D
D
D
A
D
D

K
K
K
K
K
A
K

W
W
W
W
W
W
A

M
M
M
M
M
M
M

A
A
A
A
A
A
A

M
M
M
M
M
M
M

Q
Q
Q
Q
Q
Q
Q

N
N
N
N
N
N
N

KD (μM) IC50 (μM)*
4.19 ± 0.22
>10
NB
NB
3.18 ± 0.43
NB
>10

F3
H6K
L7V
M8L
K10H
W11F

D
D
D
D
D
D

I
I
I
I
I
I

A
A
A
A
A
A

L
L
L
L
L
L

Q
Q
Q
Q
Q
Q

H
K
H
H
H
H

L
L
V
L
L
L

M
M
M
L
M
M

D
D
D
D
D
D

K
K
K
K
H
K

W
W
W
W
W
F

M
M
M
M
M
M

A
A
A
A
A
A

M
M
M
M
M
M

Q
Q
Q
Q
Q
Q

N
N
N
N
N
N

0.67 ± 0.03*
1.20 ± 0.01*
2.02 ± 0.48*
0.77 ± 0.32*
>10*
2.23 ± 1.26*

ΔN2ΔC2
ΔN5
ΔC4
ΔN3ΔC3

–
–
D
–

–
–
I
–

A
–
A
–

L
–
L
L

Q
–
Q
Q

H
–
H
H

L
L
L
L

M
M
M
M

D
D
D
D

K
K
K
K

W
W
W
W

M
M
M
M

A
A
–
A

M
M
–
–

–
Q
–
–

–
N
–
–

2.84 ± 0.38*
NB
NB
NB

F3 peptide binding to SOCS2 was measured by ITC and SPR; ITC values are average ± range, derived from two independent experiments. *SPR values are mean ± S.D., derived from three independent
experiments. Bold highlights residue changes. NB no binding. SPR curves are shown in Supplementary Fig. 10a. Source data are provided as a Source Data ﬁle.
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Fig. 2 The SOCS2-SH2 domain contains an exosite that enhances its ability to bind phosphorylated ligands. Representative ITC curves showing a
enhanced binding of the SOCS232–198-EloB/C complex to a phosphorylated peptide derived from the GHR (pY595) in the presence of the F3 peptide (black:
+ F3; green: no F3) and b enhanced binding of the SOCS2 B/C complex to F3 in the presence of the GHR pY595 peptide (black: +pY595; blue: no pY595). c
SOCS2 afﬁnity enrichment. HepG2 cells were treated with pervanadate to increase phosphorylation, lysed, and incubated with recombinant GST or GSTSOCS232–198-EloB/C (GST-SOCS2) in the presence or absence of the GHR pY595 and F3 peptides. GST-enriched protein complexes were assessed by
immunoblot (IB) with anti-phosphotyrosine antibodies (anti-pY; left panel). Protein input by Coomassie gel (right panel). Representative of two independent
experiments. d Binding afﬁnities between the three homologous non-phosphorylated peptides identiﬁed by phage display, and SOCS232–198-EloB/C preincubated with GHR pY595, assessed by ITC. Related to Supplementary Table 2. NB no binding detected e Halo-SOCS2 (H-S2) labeled with JF503 showed
speciﬁc FLIM-FRET interaction with mRuby3-F3-Myc fusion protein (mR3-F3). A FRET interaction shortens the ﬂuorescence lifetime of the donor (JF503).
HEK293T cells expressing Halo-SOCS2 and/or mRuby3-F3-Myc (or mRuby3-Myc), or positive control Halo-mRuby3 (H-mR3), as indicated, were stained
with Halo ligand JF503 and imaged by ﬂuorescence lifetime imaging microscopy (FLIM). Lefthand side images show ﬂuorescence intensity. Righthand side
images (FLIM) show lower ﬂuorescence lifetimes (rainbow scheme skewed towards red/yellow) in cells expressing SOCS2 and mRuby3-F3-Myc, than cells
expressing only SOCS2, or SOCS2 and mRuby3 without F3. Images displayed are identical with respect to instrumentation, analysis and display settings, and
are representative of three independent experiments. FLIM images are displayed with a rainbow color scale, with lower and upper limits of 3200 ps and
4100 ps (lifetime), respectively. The plot shows lifetime ﬂuorescence as mean ± S.D. n = 18–23 images collated from three independent experiments (5–12
images from each experiment). *p < 0.001 (one-way ANOVA with Tukey HSD post hoc test). H = Halotag. Additional images are shown in Supplementary
Fig. 3. f F3 enhances SOCS2 binding to GHR. 293T-GHR cells were transfected with constructs expressing Flag-SOCS2 and GST-F3-Myc and treated with
50 ng/mL growth hormone (GH) prior to cell lysis. Anti-Flag-SOCS2 immunoprecipitates were analyzed by immunoblotting for interaction with GST-F3Myc, GHR, and tyrosine-phosphorylated (pY) proteins using the appropriate antibodies. Representative of two independent experiments. Related to
Supplementary Figs. 4 and 7. Source data are provided as a Source Data ﬁle.
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Fig. 3 The crystal structure of F3 in complex with SOCS2, reveals F3 as an α-helix bound to a site distal from the pTyr-binding pocket. a Cartoon and
surface representation of the F3 (green)/SOCS2 (cyan)/Elongin B (light blue-purple)/Elongin C (magenta) 3.1 Å crystal structure. b Notably, F3 binds as
an α-helix on the opposite side to the pTyr-binding pocket, cradled between the ESS and phosphotyrosine binding loop. c Ribbon diagram of the SOCS2SH2 (white) and F3 structure showing the detailed side-chain interactions. The SOCS2-ESS and canonical SH2 domain make multiple contacts with the F3
peptide. Seven key residues within the SOCS2-ESS, the loop connecting ESS and α-helix A, the BC loop, and β-strand D, make key contacts with F3 residues
and are highlighted in yellow. Dashed lines indicated polar interactions between F3 (His6) and residues on SOCS2 F3 peptide: carbon = green; oxygen =
red; nitrogen = blue. Figures were generated using The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.

(without F3), indicating that SOCS2 interacts with F3 in intact
cells (Fig. 2e and Supplementary Fig. 3). To further conﬁrm that
binding to phosphorylated proteins was enhanced by F3, 293TGHR cells were co-transfected with constructs encoding FlagSOCS2 and GST-F3-Myc and treated with GH prior to lysis.
Immunoblot analysis of anti-Flag immunoprecipitates indicated
that GST-F3-Myc is efﬁciently bound to Flag-SOCS2, enhancing
its ability to enrich GHR and phosphorylated JAK2 (Fig. 2f).
Mutation of R96C in the SOCS2-SH2 domain, disrupts binding to
phosphopeptide20, but not F3 (Supplementary Fig. 7), and
was used to conﬁrm that SOCS2 enrichment of GHR and JAK2
was phosphotyrosine dependent. Conversely, GST-F3 afﬁnity
enrichment further validated the interaction with SOCS2 and
showed an enhanced association of multiple tyrosinephosphorylated proteins in the presence of SOCS2 (Supplementary Fig. 4).
F3 binds as an alpha-helix in a unique exosite on the SOCS2SH2 domain. To understand how F3 binding to the SOCS2-SH2
domain enhanced its interaction with phosphorylated target
proteins, structural studies were performed using both NMR and
X-ray crystallography. A SOCS2 construct with a cluster of three
mutations K115A/K117A/Q118A (SOCS232–198-KKQ) previously
reported to reduce surface conformational entropy and improve
crystallization35 was used, in complex with elongins B and C, and
bound to the shortest form of F3 that retained binding (residues
3–14, ALQHLMDKWMAM; Table 1). Crystals of a 1:1:1:1
complex (F3:SOCS2:EloB:EloC) were obtained and data processed to 3.1 Å. The structure was determined by molecular
replacement using the SOCS2/Elongin BC as a model (PDB:

2C9W6) and reﬁned to Rwork and Rfree values of 0.2271 and
0.2667, respectively (Supplementary Table 5). The overall structure of the SOCS2-SH2 domain and SOCS box in complex with
elongins B and C (Fig. 3a) accorded well with previously published structures of SOCS235, with an R.M.S.D of 0.6 Å across all
Cα (DALI) apo SOCS2 (PDB: 5BO4 chain A) and 1.1 Å when
aligned with a phosphopeptide-bound structure (PDB:
6I4X) (Supplementary Fig. 6).
F3 bound as an α-helix on the opposite side to the phosphopeptide binding site, in a shallow groove formed by the pTyr-binding
loop (deﬁned as the BC loop) and the ESS helix (Fig. 3). Residues
4–14 of the peptide were visible and the buried surface area of F3
when in contact with SOCS2 is 400Å2 (PISA36). The interaction
surface is largely hydrophobic. The side chains of Ala33, Leu36,
Ala37, Leu40 from the ESS helix and Leu81, Leu82, and Tyr99 from
the SH2 domain, form a cradle to complement the hydrophobic
face of the F3 helix, consisting of F3 residues Leu7, Met8, and
Trp11. The interaction of the Met14 side chain on F3 with the
peptide bond between SOCS2-D79 and Tyr80 further extends the
surface. In addition, F3-His6 forms a polar network with side chains
of Tyr49 and Asp74, although the resolution precludes a precise
mapping of the interactions (Fig. 3c).
The crystallographic data was strongly supported by NMR
analysis, with Ala34, Arg41, Glu42 (ESS), Ser75, Ser78, Tyr80 (BC
loop), and Gly102 and Val122 in SOCS2 showing signiﬁcant
chemical shift perturbations (CSPs) upon F3 binding37 (Fig. 4a, b).
The structure was further validated by mutagenesis of both the
peptide (Table 1) and SOCS2 (Table 2). An alanine scan of F3
peptide residues from positions 6 to 11 showed that all residues
had a signiﬁcant effect on binding afﬁnity, with the exception of
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Asp9, which is the only residue in this region that does not
contact SOCS2, but rather points into solution. Mutation of the
hydrophobic residues Leu7, Met8, and Trp11 to smaller
hydrophobic residues retained binding, indicating that the
hydrophobic surface is not signiﬁcantly altered by these more
conservative mutations.
6

Two key polar residues were identiﬁed in F3, with alanine
substitutions of His6 and Lys10 abrogating binding. His6 cannot
be substituted for alanine, but can be substituted for lysine, which
can presumably replicate the polar interactions with SOCS2Tyr49 and Asp74. Although electron density for the full
Lys10 side chain is not visible, the most favorable rotamer for

NATURE COMMUNICATIONS | (2021)12:7032 | https://doi.org/10.1038/s41467-021-26983-5 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26983-5

ARTICLE

Fig. 4 The crystallographic F3/SOCS232–198-EloB/C interface is supported by NMR analysis. a F3-bound SOCS2 crystal structure (cyan) with residues
displaying NMR chemical shift perturbations on F3 binding, mapped on the surface. Chemical shift perturbations caused by F3 binding are highlighted in
light orange (>σ) and orange (>2σ), corresponding to Fig. 4b. Orange residues (>2σ) are labeled in black. pTyr location corresponds to PDB:6I4X. b 1H15N
chemical shift perturbation of individual SOCS2 residues on F3 binding. Chemical shift perturbations (CSPs) are calculated as Δ1H and Δ15N of assigned
backbone residues of SOCS2-SH232–159. σ represents the standard deviation of all calculated chemical shift perturbations. CSPs above σ are considered
signiﬁcant. Sigma: 1 standard deviation of all chemical shift changes. Sigma and two-sigma were used as cutoffs to identify residues with the greatest CSP.
c F3 binding reduces the dissociation rate of pTyr peptide. On and off rates in the presence and absence of F3. SPR with a SOCS2 titration was performed to
observe GHR pY595 peptide association (left panels) and dissociation (right panels) curves. The koff (dissociation rate) is 0.245 ± 0.003 sec−1 (-F3) and
0.0235 ± 0.001 sec−1 (+F3). RU response units. Data shown are from a representative experiment. All replicates and data ﬁtting are shown in
Supplementary Fig. 10b. Source data are provided as a Source Data ﬁle.

Table 2 Mutation of SOCS2 impacts the binding of F3, but
not GHR pY595 peptide.
Location
SOCS2 mutation
WT
L36A
ESS
L40F
ESS
L40A
ESS
R41A
ESS
Q45A
ESS
Y49F
βA
S78A
BC loop
Y99A
βD
L81F
βC
L82F
βC
L81, 82F βC

GHR pY595
(μM)

F3 (μM)

GHR pY595 + F3
(μM)*

1.08 ± 0.07
0.80 ± 0.02
1.03 ± 0.07
1.76 ± 0.21
1.18 ± 0.54
1.32 ± 0.03
0.98 ± 0.01
2.03 ± 0.05
1.88 ± 0.01
1.17 ± 0.04
0.93 ± 0.34
1.08 ± 0.07

0.67 ± 0.03
ND1
0.81 ± 0.02
>50
0.89 ± 0.05
0.60 ± 0.34
0.79 ± 0.01
ND
ND
1.53 ± 0.03
ND
0.67 ± 0.03

0.15 ± 0.02
0.50 ± 0.02
0.29 ± 0.02
0.46 ± 0.08
0.25 ± 0.07
0.22 ± 0.03
0.18 ± 0.01
1.84 ± 0.4
1.75 ± 0.27
0.45 ± 0.02
1.94 ± 0.27
0.15 ± 0.02

IC50 values were determined by SPR; 1ND not detectable.
*Enhanced GHR pY595 afﬁnities were measured using 10 μM F3 and 100 nM SOCS2. Values are
mean ± S.D., derived from three independent experiments. Source data are provided as a Source
Data ﬁle.

lysine would position the terminal amine at an ideal distance to
interact with the cluster of backbone carbonyls formed from
residues His77 and Tyr80 and both side chain and carbonyl of
Ser75. This is consistent with the loss of binding upon
mutagenesis of Lys10 to alanine, but slight retention of binding
when substituted for histidine, which while shorter, might still be
able to hydrogen bond to nearby carbonyls such as that of Ser78.
NMR data showing chemical shift perturbations in this region
upon F3 binding is also supportive of this interaction, with Arg41,
Ser75, Ser78, Tyr80, Gly102, and Val122 in SOCS2 showing
signiﬁcant CSPs (>2σ) on F3 binding (Fig. 4a, b).
Mutagenesis of the F3 binding site on SOCS2 complemented
the peptide mutagenesis and conﬁrmed the crystallographic
analysis (Fig. 5a and Table 2). Substitution of Leu36, Leu40,
Leu81, and Tyr99 with other hydrophobic residues had a
signiﬁcant effect on F3 binding, with L81F and Y99A abrogating
binding completely, conﬁrmed by their inability to enhance GHR
pY595 binding. L40A and L36A retained the ability to enhance
GHR pY595 binding in the presence of F3, indicating there was
some residual F3 binding. L82F had a moderate effect on the
ability to bind F3 and enhance GHR pY595, and the L40F
substitution was accommodated without a signiﬁcant effect on
binding. Mutation of Tyr49 to phenylalanine did not impact
GHR pY595 or F3 binding, suggesting that Asp74 is sufﬁcient to
maintain the interaction with His6 in F3. Mutation of residues
proposed to interact with Lys10 cannot be mutated, as they are all
backbone carbonyls. Of the mutations tested, only S78A had a
direct effect on GHR binding. In the higher resolution structures
of SOCS2 (e.g., 2C9W6), the S78 side chain H-bonds with the

peptide backbone, and mutation presumably affects the conformation of the BC loop.
F3 displays a high degree of selectivity for the SOCS2-SH2
domain. Several SH2 domain-containing proteins were tested for
binding to F3 (CIS, SOCS3, and SH2B). Of these, only the closely
related SOCS protein CIS, which shares 45% a.a. identity with
SOCS2 within the SH2 domain38, showed detectable binding by
ITC (13.74 μM); albeit considerably weaker than that observed for
SOCS2 (1 μM). Notably, F3 binding to CIS still resulted in a
fourfold enhancement of pTyr-peptide binding (Supplementary
Fig. 5b), suggesting that the exosite phenomenon might extend to
other SOCS family SH2 domains and that at least for CIS, an “F3like” peptide could result in comparable enhancement of pTyrbinding afﬁnity. Sequence alignment indicates that although key
SOCS2-ESS residues involved in interacting with F3 differ in CIS,
they are largely conserved; for instance, Leu40 in SOCS2 (corresponding to Phe74 in CIS) (Supplementary Fig. 5a, c). Consistent with this, CIS-F74L and SOCS2-L40F had no impact on F3
binding (Table 2 and Supplementary Fig 5b). Sequence alignment
of CIS and SOCS2 suggested that the two phenylalanine residues
in CIS (Phe74 and Phe116), instead of the two opposing SOCS2
leucines (Leu40 and Leu82), were likely to partially block F3
interaction. However, reverting the CIS phenylalanine residues to
leucine also failed to rescue F3 binding (CIS-F74L, F116L; Supplementary Figs. 5b, 10a). Although it is still unclear why CIS
binds with lower afﬁnity to F3, it seems likely that differences in
multiple residues within both the ESS and β-strand D, collectively
result in the reduced afﬁnity (Supplementary Fig. 5c).
F3 enhances SOCS2-SH2 afﬁnity for pTyr ligands by reducing
the rate of dissociation. Although F3 binding efﬁciently enhances SOCS2-SH2 domain afﬁnity for pTyr ligands, our structure
shows that F3 does not directly contact residues involved in
binding phosphotyrosine or residues within the hydrophobic +3
binding pocket. Furthermore, no single SOCS2 residue was
identiﬁed by mutagenesis, which contributed to both F3 and
pTyr-peptide binding, nor did an overlay of the SOCS2/
F3 structure with that of SOCS2 bound to a pTyr-peptide (PDB:
6I4X) reveal any global structural differences (Supplementary
Fig. 6). Given these observations, we speculated that F3 might
function by pre-ordering the BC loop for pTyr engagement. We
therefore performed direct binding experiments to measure the
on and off rates in the presence and absence of F3. F3 binding
caused a signiﬁcant (~10-fold) reduction in the rate of dissociation (koff: 0.245 ± 0.003 to 0.0235 ± 0.001 sec−1 with F3) (Fig. 4c;
Supplementary Fig. 10b). Thus, F3 binding appears to stabilize
the pTyr-binding pocket, signiﬁcantly inhibiting dissociation of
pTyr ligands, and consequently enhancing afﬁnity.
F3 enhances SOCS2 inhibition of GH signaling in A549 cells.
Several SOCS2 mutations (including L36A, Y99A, and L81F)
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Fig. 5 F3 binding stabilizes SOCS2 and enhances SOCS2 inhibition of GH signaling. a F3-bound SOCS2 crystal structure highlighting residues in magenta
that were mutated and tested by SPR. Red labels indicate mutations that disrupted F3 binding. Related to Table 2. b 293T cells were transfected with
constructs for wild-type Flag-SOCS2 or SOCS2 with key F3-contacting residues mutated, with and without GST-F3-Myc expression. Cells were treated with
GH and lysed prior to immunoprecipitation of SOCS2 and immunoblotting with anti-Myc antibodies. All three mutations signiﬁcantly reduced SOCS2
interaction with F3, with SOCS2-L81F resulting in complete loss of F3 interaction. m1: SOCS2-L36A; m2: SOCS2-Y99A, m3: SOCS2-L81F; IP
immunoprecipitation. Representative of two independent experiments. c A549 cells with stable expression of HA-GHR (A549-GHR) were treated
overnight with doxycycline (dox) to induce Halo-SOCS2 expression and then stimulated with 50 ng/mL GH for up to 7 h, prior to lysis and analysis by
immunoblotting with antibodies to the indicated proteins. Representative of four independent experiments. d A549-GHR cells were transfected with FlagF3-Myc constructs and then treated overnight with doxycycline (dox) to induce Halo-SOCS2 expression. Cells were then treated with 50 ng/mL GH for 0,
10, 20, 30, 40, 50, 60 min, lysed, and analyzed by immunoblotting with antibodies to the indicated proteins. p phosphorylated; T total (F3). Representative
of two independent experiments. e A549-GHR cells were transfected with Flag-F3-Myc constructs (F3) prior to overnight dox treatment to induce wildtype (WT) or mutant Halo-SOCS2 proteins. Cells were then treated with 50 ng/mL GH for 30 min, lysed, and analyzed by immunoblotting with antibodies
to the indicated proteins. p phosphorylated; T total. Representative of three independent experiments. f Densitometric analysis of pSTAT5 bands relative to
WT (no dox, no F3); derived from three independent experiments including data shown in e and in Supplementary Fig. 8. Data shown are mean ± S.D. and
were analyzed using a paired t test. *p = 0.025, **p = 0.0052. Source data are provided as a Source Data ﬁle.
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were identiﬁed which disrupted F3, but not pTyr binding (Table 2
and Fig. 5a). To validate the SOCS2/F3 interaction in cells, wildtype and mutant Flag-tagged human SOCS2 constructs were
generated and expressed in 293T cells, together with a GST-F3Myc construct. Immunoprecipitation of Flag-SOCS2 and SOCS2
mutants and immunoblotting for the presence of F3, revealed
SOCS2-L36A and SOCS2-Y99A still retained weak binding to F3,
while SOCS2-L81F completely lost F3 binding (Fig. 5b).
SOCS2 has been reported to inhibit GH signaling and STAT5
phosphorylation39. To examine the impact of F3 binding on
SOCS2 function, we generated A549 cells with stable expression
of HA-GHR and a Halo-tagged SOCS2 fusion protein under
a doxycycline (dox)-inducible promoter. Dox-induction of HaloSOCS2 partially inhibited GH-induced STAT5 phosphorylation,
consistent with previous reports13,39 (Fig. 5c). Consistent with the
enhanced afﬁnity conferred by F3 binding, introducing Flag-F3Myc into the A549/HA-GHR/Halo-hSOCS2 system modestly, but
consistently enhanced SOCS2 inhibition of STAT5 phosphorylation (Fig. 5d–f; Supplementary Fig. 8), in particular at 10–30 min
GH treatment (Fig. 5d). In our experience the dox-inducible
systems are difﬁcult to regulate, perhaps accounting for the
relatively modest impact of F3, compared with the increased
afﬁnity conferred by F3 as measured by SPR and ITC. Mutation
of the F3 binding site on SOCS2 (L81F) prevented F3-mediated
enhancement of SOCS2 inhibitory function, whereas mutation of
the pTyr-binding site (R96C) reduced SOCS2 inhibition of GH
signaling. The SOCS2-L81F, R96C double mutation abrogated
both inhibition by SOCS2 and further enhancement by F3
(Fig. 5e, f; Supplementary Fig. 8). Thus, the biophysical
enhancement of pTyr-binding afﬁnity conferred by F3 binding
to the SOCS2-SH2 exosite translates to enhanced SOCS2
inhibition of GH signaling in cells.
Discussion
SOCS2 was initially identiﬁed as a key negative regulator of GH
signaling due to the “gigantic” phenotype of mice lacking Socs2,
and was subsequently shown to interact with GHR tyrosine
residues via its SH2 domain6,13,19,25,39. However, it is the emerging relationship between SOCS2, immunity, and cancer27,33,38,40
that has generated interest in understanding the role of SOCS2 in
cancer etiology. SOCS2 is highly upregulated in androgeninduced prostate cancers and has been shown to promote cancer cell growth, with a reduction in SOCS2 levels inhibiting cell
proliferation and xenograft growth40. Clinical data also suggest
that patients with high SOCS2 expression are more likely to
experience biochemical tumor relapse41. In the immune system,
SOCS2 is an IFNγ signature gene in mononuclear phagocytes
inﬁltrating primary human melanoma, and in mouse models acts
to limit adaptive anti-tumoral immunity and DC-based priming
of T cells30. Understanding how the SOCS2-SH2 domain functions and its full complement of interacting partners will be critical to determine whether SOCS2 might be a suitable target for
therapeutic intervention.
The SH2 domain is the prototypical modular signaling domain
and binds its cognate pTyr ligands in a deﬁned “two-pocket”
paradigm42. Using phage display we discovered three nonphosphorylated peptides with a common core motif that bound
SOCS2 and had the unique ability to allosterically enhance the
afﬁnity of the SH2 domain for phosphorylated peptide ligands
and proteins. The peptides therefore led us to identify an exosite
on an SH2 domain that positively inﬂuences ligand binding.
Introducing the exemplar F3 peptide into cells enhanced the
ability of SOCS2 to inhibit STAT5 phosphorylation, conﬁrming
the increase in afﬁnity translated to a biological outcome in a
relevant signaling cascade.

ARTICLE

The SOCS2-SH2 domain has the canonical SH2 structural
elements (three β-strands ﬂanked by two α-helices) and an
additional N-terminal α-helix (ESS) unique to the SOCS family
proteins. As in other SOCS proteins, the SOCS2-ESS directly
contacts the phosphotyrosine binding loop (BC loop), positioning
it for phosphotyrosine binding6,7,13. The crystal structure of
SOCS2 in complex with F3 (1.68 μM), revealed F3 bound as an αhelix nestled between the ESS and the BC loop, on the opposite
side of the pTyr pocket. The 15N-1H HSQC spectrum of the F3
peptide in the absence of SOCS2 displayed typical random-coil
chemical shifts (Supplementary Fig. 11), suggesting it does not
form a helix in the absence of protein and presumably requires
contact with SOCS2 residues to form the secondary structure.
This also explains why truncation of the non-conserved F3 residues, which would disrupt helix formation, resulted in the loss of
binding to SOCS2 (Table 1).
Surprisingly, neither structural alignment of F3-bound SOCS2
with pTyr-bound SOCS235, nor NMR analysis on F3 binding,
revealed any major perturbation of SH2 residues that would
obviously impact phosphotyrosine binding. On further investigation, we observed a signiﬁcantly slower dissociation rate for
phosphorylated peptides when F3 was bound, which accounts for
the increased afﬁnity. Given that the crystal structures in the
presence and absence of F3 (within the limits of available resolution) are essentially indistinguishable, but F3 binding signiﬁcantly decreases the off-rate of bound phosphopeptide, the
most likely explanation is that F3 stabilizes the conformation of
the BC loop in its bound form and hinders dissociation events.
The F3-driven cooperative increase in binding afﬁnity observed
both in vitro and in vivo suggests the SOCS2-SH2 domain may
have additional non-canonical interactions that we are unaware
of. There is a precedent within the SOCS family, given the SOCS1
and SOCS3-SH2 domains interact with a GQM motif on the
JAK1, JAK2, and TYK2 kinase domains; however, this interaction
interface is quite distinct from the F3 exosite and does not impact
on binding to phosphorylated ligands9,43,44. The SOCS2-SH2
domain has the capacity to bind two phosphopeptides simultaneously, with one peptide occupying the canonical site and the
second peptide binding in an anti-parallel direction35. Again, the
non-canonical site does not overlap with the F3 exosite, but this is
further evidence that there is still more to understand for the
SOCS2 inhibitory signaling cascades.
Protein interaction with the SOCS2 exosite would provide an
additional level of biological speciﬁcity, further to that provided
by the phosphotyrosine motif, and has the potential to greatly
expand the range of SOCS2-SH2 targets. This possibility led us to
search for endogenous proteins which might occupy the SOCS2
exosite. The central sequence motif (including the tolerated
residue changes) was used to search the NCBI human protein
databases and although a number of candidate proteins were
identiﬁed, peptides derived from these proteins did not interact
with SOCS2 (Supplementary Table 3). This list is by no means
exhaustive, particularly when an “F3-like” ligand may be linear,
an α-helix or non-contiguous. It is also possible that another,
non-homologous sequence may exist that binds to this site, which
may not have been present in the phage display library (or was
not able to form an alpha-helix), and other approaches, such as
proteomic analysis of SOCS2 complexes, may prove more fruitful.
The SOCS2 exosite could potentially be exploited to enhance
SOCS2 suppression of the inﬂammatory disease. In mice, loss of
SOCS2 biases towards CD4+ Th2 differentiation, suggesting
patients with allergic diseases such as atopic dermatitis and
asthma may beneﬁt from enhanced SOCS2 expression or
activity27. In cancer patients, SOCS2 expression is associated with
both a better and worse prognosis depending on the cancer type.
For example, high SOCS2 levels correlate with increased survival
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in patients with hepatocellular carcinoma (HCC)45,46 and invasive breast cancer47, whereas in metastatic melanoma patients,
SOCS2 is a key component of an IFNγ-signature associated with
increased survival30. This apparent dichotomy may relate to the
complex role of inﬂammatory signaling, which can both drive
cancer growth and inﬂuence anti-cancer immunity. An F3mimick that enhanced SOCS2 activity has the potential to reduce
JAK/STAT and NF-κB-driven pulmonary inﬂammation, and in
particular, may beneﬁt cancer patients with HCC or prostate
cancer.
The identiﬁcation of the F3 exosite suggests SOCS2-SH2
binding afﬁnities based on one-site interactions may be substantially underestimated, particularly if proteins in the same
complex occupy the canonical pTyr site and exosite simultaneously. How widespread the exosite phenomenon might
be remains unclear. We have shown that the CIS-SH2 domain,
which shares the highest sequence similarity with SOCS2, also
contains an exosite that modulates CIS-SH2 binding to phosphorylated ligands (albeit to a lesser extent than SOCS2), indicating this phenomenon extends to at least one related SH2
domain. It is a testament to the complexities of biology that a
domain discovered in 1986 with a historic and well-deﬁned
paradigm for ligand interaction48, can still present us with some
surprises. Future studies will no doubt reveal whether our ﬁndings translate to other SOCS family members and/or to the
greater SH2 domain family.
Methods
Cloning and puriﬁcation of SOCS proteins. Full-length human SOCS21–198,
SOCS2 lacking the N-terminal region (SOCS232–198), SOCS2-SH2 lacking the
N-terminal region, and the SOCS box (SOCS2-SH232–159) and human CIS lacking
both the N-terminal region and PEST motif (Δ174–202) (CIS66–258), were cloned
into pGEX-4T. Human Elongin B (ELOB; residues 1–118) and Elongin C (ELOC;
residues 17–112) were co-cloned into pACYCDuet. Constructs encoding GSTSOCS2 or GST-CIS, were co-expressed with Elongin BC in E. coli BL21 (R3) and
induced by 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) at 18 °C for 15 h.
A full list of DNA constructs used are provided in Supplementary Table 4. 1 L
S-broth cultures were collected by centrifugation and resuspended in phosphatebuffered saline (PBS) containing 5 mM β-mercaptoethanol, 5 mM phenyl phosphate, 1 mM phenylmethylsulfonyl ﬂuoride, 20 Units DNAse, and 20 mg lysozyme,
and lysed by sonication. Supernatants were collected by centrifugation at 50,000 × g
for 20 min and puriﬁed by afﬁnity chromatography using Glutathione Sepharose
resin (GE Healthcare Life Sciences). The resin was washed with PBS containing
5 mM β-mercaptoethanol and 5 mM phenyl phosphate, prior to Tobacco Etch
virus (TEV) protease cleavage to remove GST. The trimeric SOCS2/BC complex
was ﬁnally puriﬁed by size-exclusion chromatography on a Superdex 200 16/600
column (GE Healthcare Life Sciences) in 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 150 mM NaCl, 5 mM phenyl phosphate, and 2 mM tris(2-carboxyethyl)phosphine (TCEP). SOCS2/BC complexes
containing mutant SOCS32–198 proteins were produced and puriﬁed as
described above.
Cullin5 puriﬁcation. Expression and puriﬁcation of the GST-Cullin5 N-terminal
domain (Cul51–384) have been described previously49. In brief, protein production
was induced using IPTG at 25 °C overnight. TEV cleaved protein was run on a
Superdex 200 16/60 size-exclusion column equilibrated in Tris-buffered saline
containing 5 mM β-mercaptoethanol.
Phage display. Phage display selections were performed against the GSTSOCS232–198-EloB/C complex essentially as described50,51, using a randomized 16mer peptide library fused to the gene-8 major coat protein of M13 phage. Two
sequential negative selection steps on BSA and GST were used to remove nonspeciﬁc binders. Phage were then cycled through ﬁve rounds of enrichment for
binding to the GST-SOCS232–198-EloB/C complex. Speciﬁc binding of the phage
was conﬁrmed by enzyme-linked immunosorbent assays (ELISA) and clones displaying binding to GST-SOCS2, but not to GST or BSA, were subjected to Sanger
DNA sequencing. Competitive phage-ELISAs were used to estimate the afﬁnity of
peptides bound to the GST-SOCS232–198-EloB/C complex as described52.
Isothermal titration calorimetry. All ITC titrations were performed at 298 K
using a Microcal ITC200 (GE Healthcare Life Sciences), essentially as described10.
Lyophilized peptides were obtained from Genscript and resuspended in running
buffer (25 mM Hepes pH 7.5, 150 mM NaCl, 2 mM TCEP). Typically, 12 × 3.25 μL
10

injections of a 240 μM peptide solution were titrated into a 30 μM solution of
SOCS-EloB/C. An initial injection of 0.4 μL peptide solution was performed and
removed from the analysis. To determine the pTyr-peptide afﬁnities for the
SOCS2/F3 complex, 25 μM SOCS232–198-EloB/C was pre-incubated with 60 μM F3.
Data were analyzed using Microcal Origin 7.0. The binding curves ﬁtted a singlesite binding mode and KD values were determined from duplicate experiments.
ITC curves and parameters are shown in Supplementary Fig. 9; and Supplementary
Tables 1 and 2.
Thermal shift analysis. In all, 13 μM of puriﬁed SOCS232–159 (SOCS2-SH2
domain alone) was incubated with either 50 μM GHR pY595 peptide, 50 μM F3
peptide, or both peptides in HEPES-buffered saline for 5 min before addition of
Sypro-Orange (Sigma). Samples were then dispensed in triplicate into a white 384well PCR plate (Thermo Scientiﬁc). Sample heating was performed on a C1000
Thermal Cycler (Biorad) with a programmed temperature ramp rate of 1 °C/min
beginning at 25 °C and ending at 95 °C. Sample ﬂuorescence was read in the
“FRET” channel of a CFX384 Real-Time System (Biorad). TM was obtained by
performing a Boltzmann sigmoidal non-linear ﬁt of normalized data that has been
truncated after 100% ﬂuorescence was reached. Data were analyzed in Prism 9
(version 9.0.0) for macOS.
Mutagenesis of SOCS2 and CIS. SOCS2 and CIS mutations were introduced
using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Primers for mutagenesis were purchased from Integrated DNA Technologies (Singapore). Primer sequences are listed in Supplementary Table 6.
Surface plasmon resonance measurement of SOCS protein:peptide-binding
afﬁnities. Experiments were performed on a BIACORE 4000 (GE Healthcare) at
18°C in HBS-ET (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005%
Tween 20). For measurement of GHR pY595 peptide binding, biotin-GSGS-GHR
pY595 peptide was immobilized to a Streptavidin-coated SA chip (GE Healthcare).
A reference ﬂow cell was prepared using immobilized biotin-GHR Y595 (no
phosphorylation). 100 nM SOCS proteins were pre-incubated with titrations of
phosphorylated competitor peptide (10 μM, 3.3 μM, 1.1 μM, 0.3 μM, 0.1 μM) in
HBS-ET and ﬂowed through the chip. Binding responses were measured using
multi-cycle kinetics, with 240 s injection and 120 s disassociation at a ﬂow rate of
30 μL/min. 50 mM NaOH, 1 M NaCl was used to regenerate the chip surface. F3
enhancement of GHR pY595 peptide afﬁnities was measured using a ﬁxed concentration of F3 (10 μM) and SOCS2 or CIS (100 nM) with titrations of GHR
pY595 peptide.
For measurement of F3 peptide binding, biotin-GSGS-F3 peptide was
immobilized to a Streptavidin-coated SA chip, with biotin immobilized in a
reference ﬂow cell. 1 μM SOCS proteins were pre-incubated with titrations of F3
competitor peptide (10 μM, 3.3 μM, 1.1 μM, 0.3 μM, 0.1 μM) in HBS-ET plus 5 mM
phenyl phosphate and ﬂowed through the chip using multi-cycle kinetics. Values
were derived from three independent experiments (mean values ± S.D.). Raw data
was analyzed using the Biacore evaluation software and Prism 8 (version 8.0.2).
SOCS protein with no competitor phosphopeptide was used to determine maximal
binding. The relative binding values were plotted against the Log10 of competitor
peptide and a steady-state analysis was performed to derive IC50.
Cell culture and transient transfection. Human Embryonic Kidney cells
(HEK293T; RRID:CVCL_0063), human lung adenocarcinoma A549 cells
(RRID:CVCL_0023), and human HCC HepG2 cells (RRID:CVCL_0027) were
cultured in Dulbecco’s Modiﬁed Eagle’s Medium supplemented with 100 U/mL
penicillin, 0.1 ng/ml streptomycin and 10% fetal bovine serum (Thermo). All cell
lines were tested as mycoplasma-free. HEK293T and A549 cells stably expressing
Hemagglutinin-tagged GHR were generated by lentiviral transfection and selection
in puromycin (293T-GHR and A549-GHR, respectively). HEK293T cells were
transiently transfected with pEFBOS53 constructs expressing Human Flag-SOCS2
and GST-F3-Myc, using FuGene6 (Promega) according to the manufacturer’s
instructions. A549 cells were transiently transfected with Flag-F3-Myc or GST-F3Myc (pEFBOS) constructs using Lipofectamine 2000 (Thermo Fisher) according to
the manufacturer’s instructions. HEK293T and A549 cells were lysed 48 h post
transfection for further analysis.
Stable transfection of HEK293T and A549 cells. To generate A549 cells
expressing GHR together with doxycycline-inducible Halo-tagged SOCS2 or
SOCS2 mutants, cells were ﬁrst stably transfected with an HA-tagged human GHR
construct (pQCXP) using retrovirus infection, and then with Halo-tagged human
SOCS2 and SOCS2 mutant constructs (Tre3g) using lentivirus infection.
HEK293T cells expressing mRuby3 and Halo-SOCS2 were generated using lentivirus infection. The virus was produced by transient co-transfection of Packaging
and envelop vectors in HEK293T cells using Lipofectamine 2000 (Thermo Fisher).
Packaging and envelop constructs are listed in Supplementary Table 4. Infections
were performed as described previously54. A549 cells transduced to express HAGHR were selected with 2.5 µg/mL puromycin for 7 days. HA-GHR expression was
conﬁrmed by immunoblotting and cells were transduced with Halo-tagged SOCS2
and mutant SOCS2 constructs. Halo-SOCS2 expression was induced with 1 µg/mL
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doxycycline overnight, together with 10 nM Janelia Fluor (JF)646 HaloTag (Promega; GA1120) to label Halo-SOCS2 protein. JF646 positive cells with comparable
expression were sorted using a BD FACSAria III cell sorter, prior to expansion in
culture. An example gating strategy is shown in Supplementary Fig. 13.
Afﬁnity enrichment and immunoblotting. HEK293T cells and A549 cells were
lysed in NP-40 lysis buffer [1% v/v NP-40, 50 mM HEPES, pH 7.4, 150 mM NaCl,
1 mM EDTA, 10% glycerol, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF and protease
inhibitors (Complete Cocktail tablets, Roche)]12. Cell lysates were clariﬁed by
centrifugation at 13,000 × g for 15 min at 4 °C. For afﬁnity enrichment, the
supernatant was pre-cleared with protein-A Sepharose (Sigma) prior to afﬁnity
enrichment with anti-Flag M2 afﬁnity agarose gel (Sigma) or Glutathione
Sepharose resin (GE Healthcare) for 2.5 h at 4 °C. Recovered proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically transferred to nitrocellulose membranes (Amersham). Membranes
were blocked overnight in 5% w/v BSA and incubated with primary antibody for
2 h. Anti-phosphotyrosine antibody (ab179530; 1:2000) was obtained from Millipore. Anti-STAT3 antibody (4904; 1:2000), anti-Myc antibody (3946; 1:2000), antiSTAT5 (94205; 1:3000), and anti-phospho-STAT5 (9359; 1:2000) were purchased
from Cell Signaling. Anti-phospho-JAK2 antibody was obtained from Millipore
(07-606; 1:1000) and anti-JAK2 antibody from Santa Cruz (sc-390539; 1:1000).
Anti-actin-HRP antibody (C4) was obtained from Santa Cruz (sc-47778 HRP;
1:1000). Anti-Halo antibody (G921A; 1:2000) was obtained from Promega and
anti-HA antibody (12158167001; 1:1000) from Sigma Aldrich. Rat anti-Flag antibody was a kind gift from Prof. D. Huang & Dr. L. O’Reilly (Walter and Eliza Hall
Institute). Antibody binding was visualized with peroxidase-conjugated goat antirat immunoglobulin (Southern Biotech; 3010-05; 1:10000), sheep anti-rabbit
immunoglobulin (Southern Biotech; 4010-05; 1:15000), or sheep anti-mouse
immunoglobulin (GE Healthcare; NA931-1ML; 1:10000) and the enhanced chemiluminescence (ECL) system (Amersham or Millipore).
FLIM-FRET interaction assay in live cells. HEK293T cells stably expressing HaloSOCS2 (dox-inducible) and/or mRuby3-F3 (constitutive) were induced with doxycycline (2 μg/mL) and labeled with Halo ligand JF503 (50 nM) overnight on Ibidi
chambered coverslips. Live cells were imaged on a Leica SP8 confocal microscope
with a FALCON ﬂuorescence lifetime imaging detector (80 MHz laser repetition
rate, IRF generated from reﬂected light). Fluorescence lifetime data was analyzed
using FLIMﬁt (v4.12.149). Mono-exponential ﬂuorescence lifetimes were ﬁtted
pixel-wise (11 × 11 bin) for the FLIM images, and ﬁtted image-wise for the plots
and statistical analysis.

Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The coordinates and structure factors of human SOCS2 in complex with elongins B and
C and F3 peptide generated in this study have been deposited in the RSCB Protein Data
Bank (PDB) (http://www.rcsb.org/pdb) under accession code 7M6T. The NMR
assignments generated in this study have been deposited with the Biological Magnetic
Resonance Bank (https://bmrb.io/) under accession codes 50868 (SOCS2-SH2 bound to
GHRpY peptide), which is available at, and 50869 (SOCS2-SH2 bound to GHRpY
peptide and F3 peptide), which is available at. Previously published crystal structures
used in this study are available from the PDB under accession codes 2C9W, 5BO4, and
6I4X. Source data are provided with this paper.
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